Ipilimumab-associated Sweet syndrome in a melanoma patient

J Am Acad Dermatol. 2014 Nov;71(5):e211-3. doi: 10.1016/j.jaad.2014.06.042. Epub 2014 Oct 15.

Authors

Rachel Gormley¹, Karolyn Wanat², Rosalie Elenitsas³, Julia Giles⁴, Suzanne McGettigan⁴, Lynn Schuchter⁴, Junko Takeshita³

Affiliations

¹ Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA. Electronic address: Rachel.Gormley@uphs.upenn.edu.
² Department of Dermatology, University of Iowa, Carver College of Medicine, Iowa City, IA.
³ Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA.
⁴ Department of Medicine, Hematology Oncology Division, University of Pennsylvania School of Medicine, Philadelphia, PA.

PMID: 25437997
DOI: 10.1016/j.jaad.2014.06.042

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / adverse effects*
Drug Eruptions / etiology
Drug Eruptions / pathology
Humans
Ipilimumab
Male
Melanoma / drug therapy*
Middle Aged
Skin Neoplasms / drug therapy*
Sweet Syndrome / chemically induced*
Sweet Syndrome / pathology

Substances

Antibodies, Monoclonal
Ipilimumab